[Experimental pharmacology of calcium antagonists]. 1993

T Godfraind
Laboratoire de Pharmacologie, Université Catholique de Louvain, Bruxelles, Belgique.

Calcium antagonists (calcium channel blockers) constitute a chemically heterogeneous group of drugs which block voltage-operated calcium channels of L-type. They specifically interact with the alpha 1 subunit of the calcium channel. Their mechanism of action has been demonstrated using pharmacological, electrophysiological and radiochemical techniques. Their therapeutic effects are not only related to their hemodynamic action but also to their remodeling effect in hypertrophic heart and arteries, to their anti-ischaemic action and to the preservation of vascular integrity during several pathologies. Drugs belonging to the second generation of calcium antagonists show various pharmacological profiles responsible for their tissue selectivity. The latter is a rational basis for novel therapeutic indications including atherosclerosis and cardiac failure.

UI MeSH Term Description Entries
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

T Godfraind
January 1993, Therapie,
T Godfraind
February 1985, Cardiologia (Rome, Italy),
T Godfraind
July 1984, Fortschritte der Medizin,
T Godfraind
March 1985, The American journal of cardiology,
T Godfraind
November 1988, La Revue du praticien,
T Godfraind
May 1994, Medizinische Monatsschrift fur Pharmazeuten,
T Godfraind
January 1988, Journal of cardiovascular pharmacology,
T Godfraind
December 1994, Revista espanola de cardiologia,
T Godfraind
March 1987, Schweizerische medizinische Wochenschrift,
T Godfraind
April 1984, Methods and findings in experimental and clinical pharmacology,
Copied contents to your clipboard!